Kiadis Pharma NV (XAMS:KDS) Days Payable : 0.00 (As of Dec. 2020)

View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV Days Payable?

Kiadis Pharma NV's average Accounts Payable for the six months ended in Dec. 2020 was €2.38 Mil. Kiadis Pharma NV's Cost of Goods Sold for the six months ended in Dec. 2020 was €0.00 Mil.

The historical rank and industry rank for Kiadis Pharma NV's Days Payable or its related term are showing as below:

XAMS:KDS's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 152.29
* Ranked among companies with meaningful Days Payable only.

Kiadis Pharma NV's Days Payable stayed the same from Dec. 2019 (0.00) to Dec. 2020 (0.00).

Kiadis Pharma NV Days Payable Historical Data

The historical data trend for Kiadis Pharma NV's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV Days Payable Chart

Kiadis Pharma NV Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Days Payable

Get a 7-Day Free Trial

Kiadis Pharma NV Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20
Days Payable	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of Kiadis Pharma NV's Days Payable

For the Biotechnology subindustry, Kiadis Pharma NV's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiadis Pharma NV's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiadis Pharma NV's Days Payable distribution charts can be found below:

* The bar in red indicates where Kiadis Pharma NV's Days Payable falls into.

Kiadis Pharma NV Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Kiadis Pharma NV's Days Payable for the fiscal year that ended in Dec. 2020 is calculated as

	Days Payable (A: Dec. 2020 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2019 )	+	Accounts Payable (A: Dec. 2020 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2020 )	*	Days in Period
=	( (3.94	+	3.427)	/	2 )	/	0	*	365
=	3.6835					/	0	*	365
=	N/A

Kiadis Pharma NV's Days Payable for the quarter that ended in Dec. 2020 is calculated as:

	Days Payable (Q: Dec. 2020 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2020 )	+	Accounts Payable (Q: Dec. 2020 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2020 )	*	Days in Period
=	( (1.34	+	3.427)	/	2 )	/	0	*	365 / 2
=	2.3835					/	0	*	365 / 2
=	N/A

Kiadis Pharma NV Days Payable Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiadis Pharma NV (XAMS:KDS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (XAMS:KDS) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP

Website

https://www.kiadis.com

Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (XAMS:KDS) Headlines

No Headlines